Check out our most recent article featured in FDLI >

Call for a Consultation 484-414-4093
By: Kendall PC
July 1, 2026

Top 10 Legal Mistakes MedTech and Biotech Startups Make Before Their First FDA Submission

For many biotechnology and medical device startups, preparing an FDA submission is one of the most significant milestones in the company’s history. Founders often focus intensely on engineering, clinical data, fundraising, and product development—while overlooking legal and compliance issues that can ultimately delay commercialization or reduce company value.

Investors increasingly conduct legal and regulatory diligence long before a company reaches commercialization. Likewise, the FDA expects companies to establish appropriate quality systems, documentation, and governance well before a product enters the market.

At Kendall PC, we routinely advise emerging life sciences companies from concept through commercialization. Below are ten of the most common legal mistakes we see—and how companies can avoid them.

1. Waiting Too Long to Engage FDA Regulatory Counsel

Many startups believe legal counsel becomes necessary only after product development is complete.

Legal strategy should begin alongside regulatory strategy. Decisions made early regarding intended use, promotional claims, reimbursement planning, and commercialization can significantly affect regulatory pathways and future business opportunities.

Early legal involvement helps reduce costly course corrections later.

2. Making Promotional Claims Too Early

Excitement surrounding an innovative technology often leads companies to overstate what their products can do before FDA clearance or approval.

Statements made on websites, social media, investor presentations, conference booths, or marketing materials may constitute promotional claims that attract FDA scrutiny.

Every public statement should align with the product’s regulatory status and available evidence.

3. Neglecting Intellectual Property Ownership

Many startups rely on consultants, contractors, universities, or independent developers during product development.

Without properly drafted agreements, the company may not actually own critical intellectual property.

Founders should confirm ownership of:

  • Software code
  • AI algorithms
  • Clinical data
  • Regulatory documentation
  • Product designs
  • Trade secrets
  • Trademarks

Strong IP ownership is essential for financing and acquisitions.

4. Failing to Build a Compliance Program Early

Compliance is often viewed as something companies implement after commercialization.

Regulators—and sophisticated investors—expect governance much earlier.

Foundational compliance documents may include:

  • Code of Conduct
  • Healthcare Compliance Program
  • Adverse Event Reporting Procedures
  • Promotional Review Procedures
  • Vendor Management Policies
  • Document Retention Policies
  • AI Governance Policies

These documents establish credibility and reduce operational risk.

5. Misunderstanding Medical Affairs Versus Commercial Activities

Medical Affairs personnel frequently interact with healthcare professionals before commercial launch.

Without appropriate policies, scientific exchange can unintentionally become promotional activity.

Companies should establish clear guidelines governing:

  • Scientific communications
  • Medical Science Liaisons
  • Advisory Boards
  • Publications
  • Investigator interactions
  • Unsolicited requests

6. Ignoring Sunshine Act and Healthcare Fraud & Abuse Risks

Even pre-commercial companies may compensate physicians for consulting, advisory boards, research, speaking engagements, or product evaluations.

These arrangements require careful consideration under:

Appropriate documentation significantly reduces enforcement risk.

7. Using Poorly Drafted Vendor Agreements

Startups commonly outsource:

  • Software development
  • Manufacturing
  • Clinical research
  • Marketing
  • Regulatory consulting
  • Data management

Vendor agreements should clearly address confidentiality, ownership, indemnification, cybersecurity, quality responsibilities, and regulatory compliance.

8. Overlooking Privacy and Cybersecurity

Digital health and AI-driven companies routinely collect sensitive patient information.

Organizations should evaluate:

  • HIPAA applicability
  • Business Associate Agreements
  • State privacy laws
  • Cybersecurity safeguards
  • Data retention
  • Cross-border data transfers

Privacy compliance should be integrated into product development—not added later.

9. Forgetting Commercialization Planning

FDA clearance is only one milestone.

Companies should simultaneously plan for:

  • Distribution agreements
  • Sales compliance
  • Healthcare professional interactions
  • Reimbursement strategy
  • Promotional review
  • Product training
  • Corporate governance

Legal planning should support commercialization—not delay it.

10. Assuming “We’ll Fix It Later”

Perhaps the most expensive mistake is postponing legal and compliance planning until problems arise.

Correcting deficiencies after FDA inspections, investor diligence, or acquisition negotiations often costs substantially more than proactive planning.

Building for Long-Term Success

Successful life sciences companies recognize that legal strategy is a competitive advantage—not simply a cost of doing business.

Early investment in governance, compliance, and regulatory planning builds confidence with regulators, investors, customers, and strategic partners.

How Kendall PC Helps Emerging Companies

Kendall PC partners with startups throughout every stage of growth, providing practical legal counsel that supports innovation while managing regulatory risk.

Our attorneys regularly advise clients across our practice areas on:

  • FDA regulatory strategy
  • Commercialization planning
  • Corporate formation and governance
  • Healthcare compliance
  • AI governance
  • Clinical research
  • Medical Affairs compliance
  • HIPAA and privacy
  • Distribution and licensing
  • Investor diligence support

Whether your company is preparing its first FDA submission or planning commercialization, experienced legal guidance can help position your business for long-term success. Contact us to discuss your regulatory and compliance strategy.